» Articles » PMID: 37047151

Recent Insight into the Role of Sphingosine-1-Phosphate Lyase in Neurodegeneration

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Apr 13
PMID 37047151
Authors
Affiliations
Soon will be listed here.
Abstract

Sphingosine-1-phosphate lyase (SPL) is a pyridoxal 5'-phosphate-dependent enzyme involved in the irreversible degradation of sphingosine-1-phosphate (S1P)-a bioactive sphingolipid that modulates a broad range of biological processes (cell proliferation, migration, differentiation and survival; mitochondrial functioning; and gene expression). Although SPL activity leads to a decrease in the available pool of S1P in the cell, at the same time, hexadecenal and phosphoethanolamine, compounds with potential biological activity, are generated. The increased expression and/or activity of SPL, and hence the imbalance between S1P and the end products of its cleavage, were demonstrated in several pathological states. On the other hand, loss-of-function mutations in the SPL encoding gene are a cause of severe developmental impairments. Recently, special attention has been paid to neurodegenerative diseases as the most common pathologies of the nervous system. This review summarizes the current findings concerning the role of SPL in the nervous system with an emphasis on neurodegeneration. Moreover, it briefly discusses pharmacological compounds directed to inhibit its activity.

Citing Articles

Protective Role of Sphingosine-1-Phosphate During Radiation-Induced Testicular Injury.

Wang D, Xu R, Wang Z Antioxidants (Basel). 2024; 13(11).

PMID: 39594464 PMC: 11591009. DOI: 10.3390/antiox13111322.


Regulation of cellular and systemic sphingolipid homeostasis.

Kuo A, Hla T Nat Rev Mol Cell Biol. 2024; 25(10):802-821.

PMID: 38890457 DOI: 10.1038/s41580-024-00742-y.


The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases.

Kar S, Gharai S, Sahu S, Ravichandiran V, Swain S Curr Top Med Chem. 2024; 24(28):2431-2446.

PMID: 38676503 DOI: 10.2174/0115680266288509240422112839.

References
1.
Di Pardo A, Maglione V . Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders. Front Neurosci. 2018; 12:249. PMC: 5913346. DOI: 10.3389/fnins.2018.00249. View

2.
Kennedy E, Weiss S . The function of cytidine coenzymes in the biosynthesis of phospholipides. J Biol Chem. 1956; 222(1):193-214. View

3.
Shadyro O, Lisovskaya A, Semenkova G, Edimecheva I, Amaegberi N . Free-radical Destruction of Sphingolipids Resulting in 2-hexadecenal Formation. Lipid Insights. 2015; 8:1-9. PMC: 4376205. DOI: 10.4137/LPI.S24081. View

4.
Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B, Cuvillier O . First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer. Mol Cancer Ther. 2012; 11(9):1841-51. DOI: 10.1158/1535-7163.MCT-12-0227. View

5.
Sunter G, Enver E, Akbarzade A, Turan S, Vatansever P, Gunal D . Acquired modification of sphingosine-1-phosphate lyase activity is not related to adrenal insufficiency. BMC Neurol. 2018; 18(1):48. PMC: 5911956. DOI: 10.1186/s12883-018-1049-9. View